(Q51909256)

17 April 2018

title

Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population. (English)

1 reference

17 April 2018

multicenter clinical trial

main subject

1 reference

1 reference

major depressive disorder

1 reference

1 reference

9

1 reference

17 April 2018

author name string

Pei-Xian Mao

1

1 reference

17 April 2018

Yi-Lang Tang

2

1 reference

17 April 2018

Feng Jiang

3

1 reference

17 April 2018

Liang Shu

4

1 reference

17 April 2018

Xiuling Gu

5

1 reference

17 April 2018

Ming Li

6

1 reference

17 April 2018

Mincai Qian

7

1 reference

17 April 2018

Cui Ma

8

1 reference

17 April 2018

Zhuo-Ji Cai

10

1 reference

17 April 2018

publication date

1 January 2008

1 reference

17 April 2018

published in

Depression and Anxiety

1 reference

17 April 2018

volume

25

1 reference

17 April 2018

issue

1

1 reference

17 April 2018

page(s)

46-54

1 reference

17 April 2018

Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder

cites work

1 reference

7 January 2021

Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression

1 reference

7 January 2021

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

1 reference

7 January 2021

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

1 reference

7 January 2021

A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder

1 reference

7 January 2021

Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.

1 reference

7 January 2021

A rating scale for depression

1 reference

7 January 2021

A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.

1 reference

7 January 2021

The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer

1 reference

7 January 2021

Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder

1 reference

7 January 2021

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

7 January 2021

Efficacy of escitalopram in patients with severe depression: a pooled analysis

1 reference

7 January 2021

Role of pharmacogenomics in individualising treatment with SSRIs

1 reference

7 January 2021

Optimising antidepressant use in clinical practice: towards criteria for antidepressant selection.

1 reference

7 January 2021

Therapeutic drug monitoring of non-tricyclic antidepressant drugs

1 reference

7 January 2021

A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder

1 reference

7 January 2021

Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model

1 reference

7 January 2021

Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder

1 reference

7 January 2021

The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats

1 reference

7 January 2021

A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients

1 reference

7 January 2021

Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine

1 reference

7 January 2021

Pharmacogenetics and psychopharmacotherapy

1 reference

7 January 2021

Haloperidol concentrations elevated in Chinese patients

1 reference

7 January 2021

When should a trial of fluoxetine for major depression be declared failed?

1 reference

7 January 2021

Escitalopram in clinical practice: results of an open-label trial in a naturalistic setting

1 reference

7 January 2021

Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities

1 reference

7 January 2021

Escitalopram versus citalopram: the surprising role of the R-enantiomer

1 reference

7 January 2021

R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram

1 reference

7 January 2021

Twelve-month prevalence, severity, and unmet need for treatment of mental disorders in metropolitan China.

1 reference

7 January 2021

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

1 reference

7 January 2021

Identifiers

DOI

10.1002/DA.20222

1 reference

17 April 2018

1 reference

17 April 2018